Sarepta Therapeutics, Inc.
215 First Street
Cambridge, MA -2142
United States
884 articles about Sarepta Therapeutics, Inc.
-
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
-
Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
5/5/2021
Net product sales for the first quarter 2021 of $124.9 million, a 24% increase over the same quarter of prior year
-
Sarepta Therapeutics announced Monday that its next-generation PPMO candidate, SRP-5051, showed promise in a Phase II trial when used as a treatment for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.
-
Sarepta Therapeutics to Present at Upcoming Investor Conferences - May 04, 2021
5/4/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that senior management will participate in fireside chats at two upcoming virtual investor conferences
-
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
5/3/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive results from Part A of the MOMENTUM study (Study 5051-201), a global, Phase 2, multi-ascending dose clinical trial of SRP-5051
-
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
4/30/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, May 3, 2021 at 8:30 am Eastern Time, the Company will host a webcast and conference call to present results from the 30 mg/kg arm of the MOMENTUM study, a multiple-ascending dose clinical trial of SRP-5051 for the treatment of Duchenne muscular dystrophy
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 30, 2021
4/30/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on Apr. 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 4 individuals hired by Sarepta in April 2021.
-
Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021
4/28/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, May 5, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2021 financial results and to provide a corporate update.
-
Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
4/26/2021
Sarepta Therapeutics, Inc. announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation to purchase up to 2,000,000 shares of Sarepta common stock at a price of $68.50 per share in cash.
-
Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
3/23/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route 79, The Duchenne Scholarship Program, is officially open and accepting applications.
-
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
3/18/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared new results from the ongoing study of SRP-9003 (rAAVrh74.MHCK7.hSGCB), the Company’s investigational gene therapy for limb-girdle muscular dystrophy Type 2E (LGMD2E).
-
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
3/15/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference
-
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
3/1/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2020.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 27, 2021
2/27/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 26, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 2 individuals hired by Sarepta in February 2021.
-
The U.S. FDA approved Sarepta Therapeutics’ Amondys 45 (casimersen) for patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation amenable to exon 45 skipping.
-
FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation - Feb 25, 2021
2/25/2021
The U.S. Food and Drug Administration granted approval for Amondys 45 injection for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.
-
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
2/25/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that the U.S. Food and Drug Administration has approved AMONDYS 45.
-
Sarepta Therapeutics to Present at Upcoming Investor Conferences - Feb 24, 2021
2/24/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that senior management will participate in fireside chats at two upcoming virtual investor conferences:
-
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
2/22/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2020 financial results after the Nasdaq Global Market closes on Monday, March 1, 2021. Subsequently, at 4:30 p.m. E.T.,
-
Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
2/4/2021
The four winning lesson plans are now available on sharemylesson.com Lesson plans showcase creative ways to build awareness of rare disease and to build diversity and inclusion in the classroom